Kailera points to Phase III oral obesity drug data as it tees up Foundayo rivalry
Kailera’s in-licensed oral weight loss drug is currently in a global Phase II study for obesity.
08 July 2026
08 July 2026
Kailera’s in-licensed oral weight loss drug is currently in a global Phase II study for obesity.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.